Wave Life Sciences (WVE) Financials: History & Chart

Wave Life Sciences Ltd.(WVE)

Biotechnology · Cambridge, MA

$3.52-0.23 (-6.13%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Wave Life Sciences Ltd.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Cambridge, MA

317 employees

wavelifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Paul Bolno

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	65.37M	2.27M	38.25M	17.25M	7.61M	8.70M	9.18M	83.75M	-7.68M
Cost of Goods Sold	2.26M	0.00	0.00	2.26M	0.00	2.20M	2.16M	0.00	0.00
Gross Profit	63.11M	2.27M	38.25M	14.98M	7.61M	6.50M	7.01M	83.75M	-7.68M
Gross Profit Margin	96.5%	100.0%	100.0%	86.9%	100.0%	74.8%	76.4%	100.0%	100.0%
Total Operating Expenses	281.03M	76.07M	69.54M	71.45M	63.96M	59.26M	56.81M	60.78M	56.24M
Research & Development	197.42M	51.29M	47.44M	52.81M	45.87M	43.47M	40.62M	44.65M	41.20M
Selling, General & Administrative	85.87M	24.78M	22.10M	20.90M	18.09M	17.99M	18.36M	16.14M	15.04M
Operating Income (EBIT)	-217.92M	-73.80M	-31.30M	-56.47M	-56.35M	-52.76M	-49.80M	22.97M	-63.91M
Operating Margin	-333.4%	-3248.3%	-81.8%	-327.4%	-740.7%	-606.5%	-542.8%	27.4%	832.7%
Income Before Tax (EBT)	-202.47M	-69.36M	-26.09M	-53.18M	-53.85M	-50.47M	-46.88M	29.25M	-61.78M
Interest Income	15.24M	4.72M	5.29M	3.05M	2.18M	2.37M	2.88M	3.74M	1.80M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	15.45M	4.45M	5.21M	3.29M	2.50M	2.29M	2.93M	6.29M	2.13M
Net Income	-202.47M	-69.36M	-26.09M	-53.18M	-53.85M	-50.47M	-46.88M	29.25M	-61.78M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-309.7%	-3052.6%	-68.2%	-308.4%	-707.8%	-580.2%	-510.9%	34.9%	804.8%
EBITDA	-208.82M	-71.50M	-28.99M	-54.20M	-54.12M	-50.56M	-47.64M	25.12M	-61.76M
EBITDA Margin	-319.4%	-3146.8%	-75.8%	-314.3%	-711.4%	-581.3%	-519.2%	30.0%	804.5%
Depreciation & Amortization	9.10M	2.31M	2.31M	2.26M	2.23M	2.20M	2.16M	2.16M	2.16M
EPS Basic	-1.09	-0.34	-0.13	-0.30	-0.32	-0.31	-0.29	0.18	-0.47
EPS Diluted	-1.09	-0.34	-0.13	-0.30	-0.32	-0.31	-0.29	0.17	-0.47
Weighted Average Basic Shares	202.10M	202.10M	200.17M	180.15M	167.74M	163.99M	162.53M	161.49M	131.45M
Weighted Average Diluted Shares	202.10M	202.10M	200.17M	180.15M	167.74M	163.99M	162.53M	172.29M	132.56M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	42.73M	108.30M	113.31M	3.65M	40.96M	20.08M	15.98M	14.41M
Cost of Goods Sold	8.85M	0.00	0.00	0.00	0.00	130.94M	175.43M	134.43M
Gross Profit	33.88M	108.30M	113.31M	3.65M	40.96M	-110.87M	-159.45M	-120.01M
Gross Profit Margin	79.3%	100.0%	100.0%	100.0%	100.0%	-552.2%	-997.6%	-832.6%
Total Operating Expenses	249.26M	218.71M	181.30M	166.37M	167.98M	42.51M	48.87M	173.94M
Research & Development	182.78M	159.68M	130.01M	115.86M	121.88M	130.94M	175.43M	134.43M
Selling, General & Administrative	75.33M	59.02M	51.29M	50.51M	46.10M	42.51M	48.87M	39.51M
Operating Income (EBIT)	-215.38M	-110.40M	-68.00M	-162.72M	-127.02M	-153.38M	-208.32M	-159.52M
Operating Margin	-504.1%	-101.9%	-60.0%	-4459.3%	-310.1%	-763.9%	-1303.4%	-1106.7%
Income Before Tax (EBT)	-204.38M	-97.01M	-58.19M	-161.14M	-122.45M	-150.75M	-193.64M	-146.58M
Interest Income	10.48M	N/A	N/A	N/A	30K	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	16K	N/A	22K
Other Income/Expense	11.01M	13.39M	9.81M	1.58M	4.57M	2.63M	14.68M	12.94M
Net Income	-204.38M	-97.01M	-57.51M	-161.82M	-122.25M	-149.91M	-193.64M	-146.65M
Income Tax Expense	0.00	0.00	-677K	681K	-204K	-841K	0.00	69K
Net Profit Margin	-478.3%	-89.6%	-50.8%	-4434.7%	-298.4%	-746.7%	-1211.5%	-1017.4%
EBITDA	-206.53M	-101.74M	-58.79M	-152.61M	-117.18M	-145.26M	-200.73M	-153.94M
EBITDA Margin	-483.4%	-93.9%	-51.9%	-4182.1%	-286.1%	-723.5%	-1255.9%	-1068.0%
Depreciation & Amortization	8.85M	8.66M	9.21M	10.11M	9.84M	8.11M	7.59M	5.58M
EPS Basic	-1.21	-0.70	-0.54	-2.05	-2.36	-3.82	-5.30	-5.06
EPS Diluted	-1.21	-0.70	-0.54	-2.05	-2.36	-3.82	-5.30	-5.06
Weighted Average Basic Shares	168.65M	138.28M	106.10M	78.86M	51.83M	39.23M	33.87M	28.97M
Weighted Average Diluted Shares	168.65M	138.28M	106.10M	78.86M	51.83M	39.23M	33.87M	28.97M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.